The PIPE closing and warrant exercise by Nant Capital provide near-term liquidity but increase share count. The $10M milestone tied to a Phase 3 protocol submission for PDS0301 is pending and could trigger additional funding. Monitor for the FDA protocol submission and any partnership updates for PDS0101.
Drugs in focus
PDSB drug pipeline →PDS0301
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
- Next catalyst
- None dated
What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $0.8726entry
- T+1 · 20h ago +5.90%α +7.81% · $0.9241
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
PDS Biotech reported Q3 2026 net loss of $0.11 per share, narrower than the $0.19 loss a year ago, and below the consensus estimate of a $0.09 loss. The company completed the initial close of a $22.3M PIPE led by Nant Capital, which also exercised warrants and appointed two board members, providing near-term cash runway but diluting existing holders.
Key Financial Metrics
Key Facts
- Net loss per share of $0.11 for Q3 2026, vs $0.19 in Q3 2025 and consensus estimate of $0.09 loss
- Cash and cash equivalents $15.2M as of September 30, 2026, down from $26.7M at year-end 2025
- Initial closing of a PIPE financing of up to $22.3M led by Nant Capital
- Nant Capital exercised 17.7M common warrants, converting into shares and pre-funded warrants, maintaining a 19.9% stake
- Two Nant Capital designees appointed to the board
- Operating expenses decreased to $5.9M from $8.1M year-over-year, driven by lower R&D costs
- Net loss of $7.6M for the quarter, compared to $9.0M a year ago
Financial Impact
Net loss improved by $1.4M year-over-year; cash burn reduced; PIPE provides up to $22.3M in additional funding
Risk Factors
- Cash runway limited to approximately 2 quarters at current burn rate without the full PIPE closing
- Dilution from warrant exercises and PIPE issuance
- Clinical-stage company with no approved products; reliance on successful trial outcomes and additional financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402547 |
Track record
28 reports on PDSB
7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Viewing Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers